Skip to main content

Table 6 Overview of included studies – base case (sensitivity analyses) presented

From: Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend

  Kulasingam 2003 [27] Sanders 2003 [28] Goldie 2004 [29] Taira 2004 [32] Kulasingam 2007 [39]
Country US US US US Australia
Modelling approach Markov Model Markov Model Markov Model Deterministic transmission Model Markov Model
Disease included HPV,
CIN1,2–3, CC
HPV,SIL, CC HPV,
CIN1,2–3, CC
HPV HPV,
CIN1,2–3, CC
HPV types (High Risk/ Low Risk) yes/yes 16,18,31,33,35,39,45,51,52,56,58,59,68/20,22 16,18,non 16–18/yes 16,18/- 16,18,non 16–18/yes
Target population 12 F to 85 F 12 F 13 F to ≈ 17 F 12 F to 50 F 12 F to 85 F
Time horizon 12 to 85 12 to Lifetime 12 to Lifetime 12 to Lifetime 12 to 85
Discount rates 3% 3% (0–5%) 3% 2% (0–5%) 5% (3–5%)
Perspective Societal Societal Societal Societal Societal
  Goldhaber-Fiebert 2008 [33] Kim 2008 [31] Coupe, de Melker 2009 [35] Coupe, van Ginkel 2009 [36] Kim 2009 [30]
Country US US Netherlands Netherlands US
Modelling approach Individual-based model Dynamic Model Markov Model Markov Model Hybrid model (transmission model + disease model)
Disease included HPV,
CIN1,2–3, CC
CIN, CC, other HPV-related disease HPV,
CIN1,2–3, CC
HPV,
CIN1,2–3, CC
CIN, CC, other HPV-related diseases
HPV type (High Risk/Low Risk) 16,18,non 16–18/yes 16,18/- 16,18,31,33,35,39,45,51,52,56,58,59,68/- 16,18,31,33,35,39,45,51,52,56, 58,59,66,68/- 16,18/-
Target population 9 F to Lifetime 12 F 12 F 12 F 12 F + M
Time horizon 9 to Lifetime 12 to Lifetime 12 to Lifetime 12 to Lifetime 12 to Lifetime
Discount rates 3% 3% 4% (Costs) 1.5% (Health) 4% (Costs) 1.5% (Health) 3%
Perspective Societal Societal Societal Societal Societal
  Kim, Ortendahl 2009 [34] Accetta 2010 [38] Diaz 2010 [43] Demarteau 2011 [41] Burger 2012 [42]
Country US Italy Spain France Norway
Modelling approach Individual-based Model Markov Model Micro-simulation model Markov Model Simulation model
Disease included HPV,
CIN1,2–3, CC
HPV,
CIN1,2–3, CC
HPV,
CIN1,2–3, CC
HPV,
CIN1,2–3, CC
HPV,
CIN1,2–3, CC
HPV type (High Risk/Low Risk) 16,18/- 16,18,non 16–18/yes 16,18,non 16–18/yes - 16,18,non 16–18/yes
Target population 35–45 F F 11–14 F 12 F F
Time horizon 35–45 to Lifetime 11 to Lifetime 11 to lifetime 12 to lifetime Lifetime
Discount rates 3% 3% 3% 3% (Costs) 1.5% (Health) (0–5%) 4%
Perspective Societal Societal Societal Societal Societal
  Coupe 2012 [37] Tully 2012 [40] Berkhof 2013 [44]  
Country Netherlands Canada Slovenia, Poland  
Modelling approach Individual-based model Transmission model Individual-based model  
Disease included HPV,
CIN1,2–3, CC
HPV,
CIN1,2–3, CC
HPV,
CIN1,2–3, CC
 
HPV type (High Risk/Low Risk) 16,18,31,33,35,39,45,51,52,56, 58,59,66,68/- 16,18,non 16–18/- 16,18,−/−  
Target population 10 F 18 F 12 F  
Time horizon 10 to Lifetime 80 years Not clear  
Discount rates 4% (Costs) 1.5% (Health)
(No-3%)
3% 3%  
Perspective* Societal Societal Societal  
  1. *Societal perspective – costs and QALYs are calculated based on health forgone as a result of costs falling on the healthcare budget and displacing other healthcare activities